79:
global initiative supported by a robust and transparent governance structure. The ICH association established an assembly as the over-arching governing body with the aim of focusing global pharmaceutical regulatory harmonisation work in one venue that allows pharmaceutical regulatory authorities and concerned industry organisations to be more actively involved in ICH's harmonisation work. The new assembly met for the first time on 23 October 2015.
75:. ICH had the initial objective of coordinating the regulatory activities of the European, Japanese and American regulatory bodies in consultation with the pharmaceutical trade associations from these regions, to discuss and agree the scientific aspects arising from product registration. Since the new millennium, ICH's attention has been directed towards extending the benefits of harmonisation beyond the founding ICH regions.
212:
The guideline embodying the scientific consensus leaves the ICH process and becomes the subject of normal wide-ranging regulatory consultation in the ICH regions. Regulatory authorities and industry associations in other regions may also comment on the draft consultation documents by providing their
120:
The ICH WGs are established by the assembly when a new technical topic is accepted for harmonisation, and are charged with developing a harmonised guideline that meets the objectives outlined in the concept paper and business plan. Face-to-face meetings of the WG will normally only take place during
104:
The ICH assembly brings together all members and observers of the ICH association as the overarching governing body of ICH. It adopts decisions in particular on matters such as on the adoption of ICH guidelines, admission of new members and observers, and the ICH association's work plans and budget.
78:
In 2015, ICH underwent several reforms and changed its name to the
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use while becoming a legal entity in Switzerland as a non-profit association. The aim of these reforms was to transform ICH into a truly
320:
is a rich and highly specific standardised medical terminology developed by ICH to facilitate sharing of regulatory information internationally for medical products used by humans. It is used for registration, documentation and safety monitoring of medical products both before and after a product
70:
began harmonising regulatory requirements. In 1989, Europe, Japan, and the United States began creating plans for harmonisation. The
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) was created in April 1990 at a meeting in
129:
ICH harmonisation activities fall into 4 categories: Formal ICH Procedure, Q&A Procedure, Revision
Procedure and Maintenance Procedure, depending on the activity to be undertaken. The development of a new harmonised guideline and its implementation (the formal ICH procedure) involves 5 steps:
275:
The ICH harmonised guideline moves immediately to the final step of the process that is the regulatory implementation. This step is carried out according to the same national or regional procedures that apply to other regional regulatory guidelines and requirements in the ICH regions.
116:
The ICH secretariat is responsible for day-to-day management of ICH, coordinating ICH activities as well as providing support to the assembly, the MC and working groups. The ICH secretariat also provides support for the MedDRA MC. The ICH secretariat is located in Geneva, Switzerland.
693:
Content is copied from this source, which is © ICH. Content may be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the information and material is acknowledged at all
168:
is reached when the assembly agrees, based on the report of the WG, that there is sufficient scientific consensus on the technical issues for the technical document to proceed to the next stage of regulatory consultation. The assembly then endorses the
112:
The MedDRA Management
Committee (MC) is responsible for direction of MedDRA, ICH's standardised medical terminology. The MedDRA MC has the role of managing, supporting, and facilitating the maintenance, development, and dissemination of MedDRA.
392:
141:
The WG works to prepare a consensus draft of the technical document, based on the objectives set out in the concept paper. When consensus on the draft is reached within the WG, the technical experts of the WG will sign the
53:
Harmonisation leads to a more rational use of human, animal and other resources, the elimination of unnecessary delay in the global development, and availability of new medicines while maintaining safeguards on quality,
366:
108:
The ICH Management
Committee (MC) is the body that oversees operational aspects of ICH on behalf of all members, including administrative and financial matters and oversight of the working groups (WGs).
58:, efficacy, and regulatory obligations to protect public health. Junod notes in her 2005 treatise on clinical drug trials that "bove all, the ICH has succeeded in aligning clinical trial requirements."
361:
625:
Lourenco, C.; Orphanos, N.; Parker, C. (2016). "The
International Council for Harmonisation : Positioning of the future with its recent reform and over 25 years of harmonisation work".
568:
Lourenco, C.; Orphanos, N.; Parker, C. (2016). "The
International Council for Harmonisation : Positioning of the future with its recent reform and over 25 years of harmonisation work".
17:
432:
336:
264:
is reached when the regulatory members of the assembly agree that there is sufficient scientific consensus on the draft guideline and adopt the ICH harmonised guideline.
550:
595:
Mullin
Theresa (17 Nov 2017). "International Regulation of Drugs and Biological Products". In Gallin, John I.; Ognibene, Frederick P.; Lee Johnson, Laura (eds.).
478:
Mullin
Theresa (17 Nov 2017). "International Regulation of Drugs and Biological Products". In Gallin, John I.; Ognibene, Frederick P.; Lee Johnson, Laura (eds.).
402:
279:
Information on the regulatory action taken and implementation dates are reported back to the assembly and published by the ICH secretariat on the ICH website.
437:
105:
Member representatives appointed to the assembly are supported by ICH coordinators who represent each member to the ICH secretariat on a daily basis.
219:
After obtaining all comments from the consultation process, the EWG works to address the comments received and reach consensus on what is called the
397:
412:
321:
has been authorised for sale. Products covered by the scope of MedDRA include pharmaceuticals, vaccines and drug-device combination products.
452:
341:
50:
by achieving greater harmonisation through the development of technical guidelines and requirements for pharmaceutical product registration.
233:
If, after due consideration of the consultation results by the WG, consensus is reached amongst the experts on a revised version of the
331:
537:
245:
expert draft guideline with regulatory EWG signatures is submitted to the regulatory members of the assembly to request adoption at
121:
the biannual ICH meetings. Interim reports are made at each meeting of the assembly and made publicly available on the ICH website.
829:
407:
522:
824:
814:
442:
417:
551:"International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)"
371:
309:
ICH guidelines are not binding, and instead implemented by regulatory members through national and regional governance.
809:
18:
International
Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
457:
387:
356:
292:
The ICH topics are divided into four categories and ICH topic codes are assigned according to these categories:
39:
376:
660:
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)
422:
346:
819:
32:
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
201:
occurs in three distinct stages: regulatory consultation, discussion, and finalisation of the
634:
577:
187:
is reached when the regulatory members of the assembly further endorse the draft guideline.
43:
150:
Experts' technical document is then submitted to the assembly to request adoption under
351:
67:
803:
427:
382:
47:
241:
expert draft guideline is signed by the experts of the ICH regulatory members. The
55:
495:
Clinical drug trials - Studying the safety and efficacy of new pharmaceuticals
447:
525:, Zachary Brennan, 26 October 2015, Regulatory Affairs Professionals Society
728:
497:. (thesis for Faculté de droit de Genève) Bruxelles: Bruylant. p. 107.
393:
International Federation of Pharmaceutical Manufacturers & Associations
713:
538:
ICH is now International Council for Harmonisation – a Legal Swiss Entity
72:
675:
Drug Benefits and Risks: International Textbook of Clinical Pharmacology
638:
581:
317:
38:) is an initiative that brings together regulatory authorities and
367:
European Federation of Pharmaceutical Industries and Associations
753:
718:
673:
van Boxtel, Chris J.; Santoso, Budiono; Edwards, Ralph (2008).
508:
Teasdale, Andrew; Elder, David; Nims, Raymond W. (9 Oct 2017).
783:
612:
Global Approach in Safety Testing: ICH Guidelines Explained
362:
Council for International Organizations of Medical Sciences
788:
763:
743:
688:
610:
Van der Laan, Jan Willem; DeGeorge, Joseph (11 Feb 2013).
773:
768:
758:
748:
778:
733:
217:
Stage II - Discussion of regional consultation comments:
793:
738:
723:
655:
46:
and registration. The mission of the ICH is to promote
714:
Analysis: New ICH M2 Requirements into eCTD NMV (=RPS)
180:: Endorsement of draft guideline by regulatory members
708:
161:: Confirmation of consensus on the technical document
433:
Pharmaceutical Research and Manufacturers of America
337:
Australia New Zealand Therapeutic Products Authority
614:. Springer Science & Business Media. p. 3.
408:
Ministry of Food and Drug Safety, Republic of Korea
438:Pharmaceuticals and Medical Devices Agency, Japan
510:ICH Quality Guidelines: An Implementation Guide
42:to discuss scientific and technical aspects of
403:Japan Pharmaceutical Manufacturers Association
413:Ministry of Health, Labour and Welfare, Japan
8:
597:Principles and Practice of Clinical Research
480:Principles and Practice of Clinical Research
210:Stage I - Regional regulatory consultation:
257:: Adoption of an ICH harmonised guideline
533:
531:
194:: Regulatory consultation and discussion
87:The ICH comprises the following bodies:
470:
398:International Pharmaceutical Federation
656:"Welcome to the ICH Official Website"
650:
648:
453:Food and Drug Administration (Taiwan)
342:Biotechnology Innovation Organization
7:
512:. John Wiley & Sons. p. 1.
27:Initiative to promote public health
332:Brazilian Health Regulatory Agency
44:pharmaceutical product development
25:
523:ICH Makes Organizational Changes
372:Food and Drug Administration, US
213:comments to the ICH Secretariat.
443:Regulation of therapeutic goods
418:National pharmaceuticals policy
305:M: Multidisciplinary Guidelines
627:Pharmaceuticals Policy and Law
570:Pharmaceuticals Policy and Law
1:
599:. Academic Press. p. 92.
482:. Academic Press. p. 88.
227:Stage III - Finalisation of
146:Experts sign-off sheet. The
97:MedDRA Management Committee
846:
555:European Medicines Agency
458:Uppsala Monitoring Centre
357:Common Technical Document
677:. IOS Press. p. 70.
231:experts draft guideline:
223:experts draft guideline.
205:expert draft guideline.
125:Process of Harmonisation
94:ICH Management Committee
830:International standards
784:Swissmedic, Switzerland
769:MFDS, Republic of Korea
493:Junod, Valerie (2005).
448:Swissmedic, Switzerland
40:pharmaceutical industry
825:Life sciences industry
815:Pharmaceuticals policy
689:"MedDRA/Work Products"
540:, James Lind Institute
377:Good clinical practice
302:E: Efficacy Guidelines
744:Health Canada, Canada
423:Pharmaceutical policy
347:Clinical study report
296:Q: Quality Guidelines
237:draft guideline, the
789:TFDA, Chinese Taipei
299:S: Safety Guidelines
173:technical document.
154:of the ICH process.
137:: Consensus building
249:of the ICH process.
639:10.3233/PPL-160434
582:10.3233/PPL-160434
66:In the 1980s, the
810:Clinical research
16:(Redirected from
837:
774:MHLW/PMDA, Japan
695:
692:
685:
679:
678:
670:
664:
663:
652:
643:
642:
622:
616:
615:
607:
601:
600:
592:
586:
585:
565:
559:
558:
547:
541:
535:
526:
520:
514:
513:
505:
499:
498:
490:
484:
483:
475:
271:: Implementation
21:
845:
844:
840:
839:
838:
836:
835:
834:
800:
799:
798:
704:
699:
698:
687:
686:
682:
672:
671:
667:
654:
653:
646:
624:
623:
619:
609:
608:
604:
594:
593:
589:
567:
566:
562:
549:
548:
544:
536:
529:
521:
517:
507:
506:
502:
492:
491:
487:
477:
476:
472:
467:
462:
327:
315:
290:
285:
273:
259:
196:
182:
163:
139:
127:
100:ICH Secretariat
85:
64:
28:
23:
22:
15:
12:
11:
5:
843:
841:
833:
832:
827:
822:
817:
812:
802:
801:
797:
796:
791:
786:
781:
776:
771:
766:
764:MedDRA website
761:
756:
751:
749:HSA, Singapore
746:
741:
736:
731:
726:
721:
719:ANVISA, Brazil
716:
711:
705:
703:
702:External links
700:
697:
696:
680:
665:
644:
617:
602:
587:
560:
542:
527:
515:
500:
485:
469:
468:
466:
463:
461:
460:
455:
450:
445:
440:
435:
430:
425:
420:
415:
410:
405:
400:
395:
390:
388:HSA, Singapore
385:
380:
374:
369:
364:
359:
354:
352:Clinical trial
349:
344:
339:
334:
328:
326:
323:
314:
311:
307:
306:
303:
300:
297:
289:
286:
284:
281:
272:
266:
258:
252:
251:
250:
224:
214:
195:
189:
181:
175:
162:
156:
138:
132:
126:
123:
102:
101:
98:
95:
92:
84:
81:
68:European Union
63:
60:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
842:
831:
828:
826:
823:
821:
818:
816:
813:
811:
808:
807:
805:
795:
792:
790:
787:
785:
782:
780:
777:
775:
772:
770:
767:
765:
762:
760:
757:
755:
752:
750:
747:
745:
742:
740:
737:
735:
732:
730:
727:
725:
722:
720:
717:
715:
712:
710:
707:
706:
701:
690:
684:
681:
676:
669:
666:
661:
657:
651:
649:
645:
640:
636:
632:
628:
621:
618:
613:
606:
603:
598:
591:
588:
583:
579:
575:
571:
564:
561:
557:. 2018-09-17.
556:
552:
546:
543:
539:
534:
532:
528:
524:
519:
516:
511:
504:
501:
496:
489:
486:
481:
474:
471:
464:
459:
456:
454:
451:
449:
446:
444:
441:
439:
436:
434:
431:
429:
428:Pharmacopoeia
426:
424:
421:
419:
416:
414:
411:
409:
406:
404:
401:
399:
396:
394:
391:
389:
386:
384:
383:Health Canada
381:
378:
375:
373:
370:
368:
365:
363:
360:
358:
355:
353:
350:
348:
345:
343:
340:
338:
335:
333:
330:
329:
324:
322:
319:
312:
310:
304:
301:
298:
295:
294:
293:
287:
283:Work products
282:
280:
277:
270:
267:
265:
263:
256:
253:
248:
244:
240:
236:
232:
230:
225:
222:
218:
215:
211:
208:
207:
206:
204:
200:
193:
190:
188:
186:
179:
176:
174:
172:
167:
160:
157:
155:
153:
149:
145:
136:
133:
131:
124:
122:
118:
114:
110:
106:
99:
96:
93:
90:
89:
88:
82:
80:
76:
74:
69:
61:
59:
57:
51:
49:
48:public health
45:
41:
37:
33:
19:
683:
674:
668:
659:
630:
626:
620:
611:
605:
596:
590:
573:
569:
563:
554:
545:
518:
509:
503:
494:
488:
479:
473:
316:
308:
291:
278:
274:
268:
261:
260:
254:
246:
242:
238:
234:
228:
226:
220:
216:
209:
202:
198:
197:
191:
184:
183:
177:
170:
165:
164:
158:
151:
147:
143:
140:
134:
128:
119:
115:
111:
107:
103:
91:ICH Assembly
86:
77:
65:
52:
35:
31:
29:
820:Drug safety
709:ICH website
633:(1–4): 86.
576:(1–4): 82.
804:Categories
729:EC, Europe
288:Guidelines
83:Structure
325:See also
73:Brussels
739:FDA, US
662:. 2022.
235:Step 2b
185:Step 2b
178:Step 2b
171:Step 2a
166:Step 2a
159:Step 2a
62:History
694:times.
318:MedDRA
313:MedDRA
269:Step 5
262:Step 4
255:Step 4
247:Step 4
243:Step 3
239:Step 3
229:Step 3
221:Step 3
203:Step 3
199:Step 3
192:Step 3
152:Step 2
148:Step 1
144:Step 1
135:Step 1
56:safety
779:PhRMA
734:EFPIA
465:Notes
379:(GCP)
794:WSMI
759:JPMA
754:IGBA
30:The
724:BIO
635:doi
578:doi
36:ICH
806::
658:.
647:^
631:18
629:.
574:18
572:.
553:.
530:^
691:.
641:.
637::
584:.
580::
34:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.